Top

Advances in Therapy

Published in:

Open Access 01-03-2020 | Diabetes | Original Research

Long-Term, Real-World Safety and Efficacy of Teneligliptin: A Post-Marketing Surveillance of More Than 10,000 Patients with Type 2 Diabetes in Japan

Authors: Takashi Kadowaki, Masakazu Haneda, Hiroshi Ito, Kazuyo Sasaki, Miyuki Matsukawa, Yuka Yamada

Published in: Advances in Therapy | Issue 3/2020

Abstract

Introduction

Teneligliptin is a dipeptidyl peptidase 4 inhibitor that was approved for the treatment of type 2 diabetes mellitus (T2DM) in Japan in 2012. We performed a long-term post-marketing surveillance (RUBY) to obtain real-world evidence regarding the safety and efficacy of teneligliptin in Japan.

Methods

This 3-year follow-up RUBY surveillance registered patients with T2DM who started treatment with teneligliptin between May 2013 and February 2015 in Japan. Collected data included demographics, treatments, adverse drug reactions (ADRs) and laboratory variables. Data were evaluated in all patients and in patients divided according to baseline renal function across categories of estimated glomerular filtration rate (G1–G5) and dialysis. Safety was assessed as the incidence of ADRs and efficacy was assessed in terms of glycaemic control, for up to 3 years.

Results

Of 11,677 patients registered, 10,696 and 10,249 were evaluable for safety and efficacy analyses, respectively. The median duration of exposure was 1096 days. ADRs occurred in 412 patients (3.85%) and were serious in 117 patients (1.09%). The most frequent ADR class was gastrointestinal disorders (0.68%), which included constipation. There were no new ADRs warranting attention beyond those already described in teneligliptin’s package insert. ADRs and serious ADRs in renal function subgroups occurred in 3.24–7.14% and 0.65–5.36% in G1–G5, and 4.49% and 1.92% in patients on dialysis, respectively. Reduction in HbA1c was sustained for 3 years after starting teneligliptin (− 0.70% ± 1.36%, p < 0.001 at 3 years). The least-squares mean changes in HbA1c adjusted for baseline were − 0.76% to − 0.66% in G1–G5 at 3 years. Glycated albumin levels decreased in patients on dialysis (− 2.92% ± 4.78% at 3 years).

Conclusion

There were no new safety or efficacy concerns about teneligliptin used in long-term, real-world, clinical settings in patients with T2DM with any stages of renal impairment.

Trial registration

Japan Pharmaceutical Information Center clinical trials database identifier: Japic CTI-153047.

Plain Language Summary

Plain language summary available for this article.

Available only for authorised users

Guariguata L, Whiting DR, Hambleton I, Beagley J, Linnenkamp U, Shaw JE. Global estimates of diabetes prevalence for 2013 and projections for 2035. Diabetes Res Clin Pract. 2014;103(2):137–49. https://doi.org/10.1016/j.diabres.2013.11.002.CrossRefPubMed

Ministry of Health, Labour and Welfare. National Health and Nutrition Survey in Japan 2016; 2016. https://www.mhlw.go.jp/file/04-Houdouhappyou-10904750-Kenkoukyoku-Gantaisakukenkouzoushinka/kekkagaiyou_7.pdf (in Japanese). Accessed 17 Sept 2019.

Nitta K, Masakane S, Hanafusa N, et al. 2017 Annual dialysis data report, JSDT Renal Data Registry. Nihon Toseki Igakkai Zasshi. 2018;51(12):699–766. https://doi.org/10.4009/jsdt.51.699 (in Japanese).CrossRef

American Diabetes Association. Glycemic targets: standards of medical care in diabetes-2019. Diabetes Care. 2019;42(Suppl 1):S61–70. https://doi.org/10.2337/dc19-s006.

Araki E, Haneda M, Kasuga M, et al. New glycemic targets for patients with diabetes from the Japan Diabetes Society. J Diabetes Investig. 2017;8(1):123–5. https://doi.org/10.1111/jdi.12600.CrossRefPubMed

Davies MJ, D’Alessio DA, Fradkin J, et al. Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2018;61(12):2461–98. https://doi.org/10.1007/s00125-018-4729-5.CrossRefPubMed

Avogaro A, Schernthaner G. Achieving glycemic control in patients with type 2 diabetes and renal impairment. Acta Diabetol. 2013;50(3):283–91. https://doi.org/10.1007/s00592-012-0442-x.CrossRefPubMed

Tuttle KR, Bakris GL, Bilous RW, et al. Diabetic kidney disease: a report from an ADA Consensus Conference. Am J Kidney Dis. 2014;64(4):510–33. https://doi.org/10.1053/j.ajkd.2014.08.001.CrossRefPubMed

Seino Y, Kuwata H, Yabe D. Incretin-based drugs for type 2 diabetes: focus on East Asian perspectives. J Diabetes Investig. 2016;7(Suppl 1):102–9. https://doi.org/10.1111/jdi.12490.CrossRefPubMedPubMedCentral

10.

Cho YM. Incretin physiology and pathophysiology from an Asian perspective. J Diabetes Investig. 2015;6(5):495–507. https://doi.org/10.1111/jdi.12305.CrossRefPubMed

11.

Yabe D, Seino Y, Fukushima M, Seino S. Beta cell dysfunction versus insulin resistance in the pathogenesis of type 2 diabetes in East Asians. Curr Diab Rep. 2015;15(6):602. https://doi.org/10.1007/s11892-015-0602-9.CrossRefPubMed

12.

Kim YG, Hahn S, Oh TJ, Kwak SH, Park KS, Cho YM. Differences in the glucose-lowering efficacy of dipeptidyl peptidase-4 inhibitors between Asians and non-Asians: a systematic review and meta-analysis. Diabetologia. 2013;56(4):696–708. https://doi.org/10.1007/s00125-012-2827-3.CrossRefPubMed

13.

Ceriello A, De Nigris V, Iijima H, Matsui T, Gouda M. The unique pharmacological and pharmacokinetic profile of teneligliptin implications for clinical practice. Drugs. 2019;979(7):733–50. https://doi.org/10.1007/s40265-019-01086-0.CrossRef

14.

Eto T, Inoue S, Kadowaki T. Effects of once-daily teneligliptin on 24-h blood glucose control and safety in Japanese patients with type 2 diabetes mellitus: a 4-week, randomized, double-blind, placebo-controlled trial. Diabetes Obes Metab. 2012;14(11):1040–6. https://doi.org/10.1111/j.1463-1326.2012.01662.x.CrossRefPubMed

15.

Kadowaki T, Kondo K. Efficacy, safety and dose-response relationship of teneligliptin, a dipeptidyl peptidase-4 inhibitor, in Japanese patients with type 2 diabetes mellitus. Diabetes Obes Metab. 2013;15(9):810–8. https://doi.org/10.1111/dom.12092.CrossRefPubMed

16.

Kadowaki T, Inagaki N, Kondo K, et al. Efficacy and safety of teneligliptin added to canagliflozin monotherapy in Japanese patients with type 2 diabetes mellitus: a multicentre, randomized, double-blind, placebo-controlled, parallel-group comparative study. Diabetes Obes Metab. 2018;20(2):453–7. https://doi.org/10.1111/dom.13079.CrossRefPubMed

17.

Kadowaki T, Kondo K. Efficacy and safety of teneligliptin in combination with pioglitazone in Japanese patients with type 2 diabetes mellitus. J Diabetes Investig. 2013;4(6):576–84. https://doi.org/10.1111/jdi.12092.CrossRefPubMedPubMedCentral

18.

Kadowaki T, Kondo K. Efficacy and safety of teneligliptin added to glimepiride in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled study with an open-label, long-term extension. Diabetes Obes Metab. 2014;16(5):418–25. https://doi.org/10.1111/dom.12235.CrossRefPubMed

19.

Kadowaki T, Kondo K, Sasaki N, et al. Efficacy and safety of teneligliptin add-on to insulin monotherapy in Japanese patients with type 2 diabetes mellitus: a 16-week, randomized, double-blind, placebo-controlled trial with an open-label period. Expert Opin Pharmacother. 2017;18(13):1291–300. https://doi.org/10.1080/14656566.2017.1359259.CrossRefPubMed

20.

Kim MK, Rhee EJ, Han KA, et al. Efficacy and safety of teneligliptin, a dipeptidyl peptidase-4 inhibitor, combined with metformin in Korean patients with type 2 diabetes mellitus: a 16-week, randomized, double-blind, placebo-controlled phase III trial. Diabetes Obes Metab. 2015;17(3):309–12. https://doi.org/10.1111/dom.12424.CrossRefPubMedPubMedCentral

21.

Kim Y, Kang ES, Jang HC, et al. Teneligliptin versus sitagliptin in Korean patients with type 2 diabetes inadequately controlled with metformin and glimepiride: a randomized, double-blind, non-inferiority trial. Diabetes Obes Metab. 2019;21(3):631–9. https://doi.org/10.1111/dom.13566.CrossRefPubMed

22.

Kadowaki T, Marubayashi F, Yokota S, Katoh M, Iijima H. Safety and efficacy of teneligliptin in Japanese patients with type 2 diabetes mellitus: a pooled analysis of two phase III clinical studies. Expert Opin Pharmacother. 2015;16(7):971–81. https://doi.org/10.1517/14656566.2015.1032249.CrossRefPubMed

23.

TENELIA^® 20 mg, 40 mg tablets. interview form, 13th version. 2018 (in Japanese). https://medical.mt-pharma.co.jp/di/file/if/tnl.pdf. Accessed 17 Sept 2019.

24.

Kadowaki T, Haneda M, Ito H, et al. Safety and efficacy of long-term treatment with teneligliptin: interim analysis of a post-marketing surveillance of more than 10,000 Japanese patients with type 2 diabetes mellitus. Expert Opin Pharmacother. 2018;19(2):83–91. https://doi.org/10.1080/14656566.2017.1420165.CrossRefPubMed

25.

Haneda M, Kadowaki T, Ito H, et al. Safety and efficacy of teneligliptin in patients with type 2 diabetes mellitus and impaired renal function: interim report from post-marketing surveillance. Diabetes Ther. 2018;9(3):1083–97. https://doi.org/10.1007/s13300-018-0416-2.CrossRefPubMedPubMedCentral

26.

Kadowaki T, Haneda T, Ito H, et al. Relationship of eating patterns and metabolic parameters, and teneligliptin treatment: interim results from post-marketing surveillance in Japanese type 2 diabetes patients. Adv Ther. 2018;35(6):817–31. https://doi.org/10.1007/s12325-018-0704-2.CrossRefPubMedPubMedCentral

27.

Matsuo S, Imai E, Horio M, et al. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis. 2009;53(6):982–92. https://doi.org/10.1053/j.ajkd.2008.12.034.CrossRefPubMed

28.

KDIGO Clinical Guideline Working Group. Chapter 1: definition and classification of CKD. Kidney Int Suppl. 2013;3(1):19–62. https://doi.org/10.1038/kisup.2012.64.

29.

Yabe D, Seino Y. Dipeptidyl peptidase-4 inhibitors and sulfonylureas for type 2 diabetes: friend or foe? J Diabetes Investig. 2014;5(5):475–7. https://doi.org/10.1111/jdi.12229.CrossRefPubMedPubMedCentral

30.

Unno Y, Ikeda R, Ochiai K, Hayashi N. Safety and efficacy of long-term combination therapy with linagliptin (Trazenta^® tablet 5 mg), a DPP-4 inhibitor, in patients with type 2 diabetes mellitus–interim report from a special drug use-results survey. J New Rem Clin. 2018;67(7):799–822 (in Japanese).

31.

Unno Y, Ochiai K, Ikeda R, Hayashi H. Long-term safety and efficacy of linagliptin (Trazenta^® tablets 5 mg), a DPP-4 inhibitor, in patients with type 2 diabetes mellitus–Interim report from special surveillance in patients who started linagliptin treatment as monotherapy. J New Rem Clin. 2018;67(6):667–88 (in Japanese).

32.

Fukuda M, Doi K, Sugawara M, Mochizuki K. Efficacy and safety of sitagliptin in elderly patients with type 2 diabetes mellitus: a focus on hypoglycemia. J Diabetes Investig. 2019;10(2):383–91. https://doi.org/10.1111/jdi.12915.CrossRefPubMed

33.

Ohmura H, Mita T, Matsuoka J, et al. Real-world data on the incidence of macrovascular complications in Japanese patients with type 2 diabetes: the Sitagliptin Registration Type 2 Diabetes-Juntendo Collaborating Project. Diabetes Ther. 2019;10(3):1099–111. https://doi.org/10.1007/s13300-019-0626-2.CrossRefPubMedPubMedCentral

34.

Umezawa S, Kubota A, Maeda H, et al. Two-year assessment of the efficacy and safety of sitagliptin in elderly patients with type 2 diabetes: post hoc analysis of the ASSET-K study. BMC Endocr Disord. 2015;15:34. https://doi.org/10.1186/s12902-015-0033-2.CrossRefPubMedPubMedCentral

35.

Murayama H, Toda M, Tsumiyama I, et al. Relationship of patient background with macro- and microvascular complications: a 2-year post-marketing surveillance of vildagliptin in nearly 20,000 Japanese diabetic patients. Expert Opin Pharmacother. 2019;20(8):1037–47. https://doi.org/10.1080/14656566.2019.1585802.CrossRefPubMed

36.

Umeki Y, Saito C, Nakamura Y, et al. Safety and efficacy of treatment with omarigliptin (MARIZEV^® Tablets) by renal function classification–Interim analysis of a post-marketing surveillance study. J New Rem Clin. 2018;67(9):1044–74 (in Japanese).

37.

Kasahara T, Tabuchi O, Kashiwagi N, Ichikawa K. Safety and efficacy of long-term therapy with dipeptidyl peptidase-4 (DPP-4) inhibitor, anagliptin (Suiny^®) in patients with type 2 diabetes mellitus - 2-year interim report I of Suiny post-marketing prospective study with type 2 diabetes mellitus in Japan (SWIM-JPN). Jpn Pharmacol Ther. 2018;46(8):1293–314 (in Japanese).

38.

Tabuchi O, Kasahara T, Kashiwagi N, Ichikawa K. Effect of dipeptidyl peptidase-4 (DPP-4) inhibitor, anagliptin (Suiny^®) on blood glucose and serum lipid in patients with type 2 diabetes mellitus - 2- year interim report II of Suiny post-marketing prospective study with type 2 diabetes mellitus in Japan (SWIM-JPN). Jpn Pharmacol Ther. 2018;46(8):1315–29 (in Japanese).

39.

Guliani A, Bishnoi A, Aggarwal D, Parsad D. Teneligliptin-associated bullous pemphigoid in an elderly man with diabetes. Postgrad Med J. 2018;94(1117):662–3. https://doi.org/10.1136/postgradmedj-2018-136044.CrossRefPubMed

40.

Kage Y, Yamaguchi Y, Uchida T, et al. Case of bullous pemphigoid associated with teneligliptin accompanied by severe mucous membrane involvement. J Dermatol. 2018;45(7):e205–6. https://doi.org/10.1111/1346-8138.14237.CrossRefPubMed

41.

Maki N, Nishie W, Takazawa M, et al. Dipeptidyl peptidase-4 inhibitor-associated bullous pemphigoid in a patient with acquired reactive perforating collagenosis. J Dermatol. 2018;45(5):e205–6. https://doi.org/10.1111/1346-8138.14254.CrossRef

42.

Tanaka H, Ishii T. Analysis of patients with drug-induced pemphigoid using the Japanese Adverse Drug Event Report database. J Dermatol. 2019;46(3):240–4. https://doi.org/10.1111/1346-8138.14741.CrossRefPubMed

43.

Kawaguchi Y, Shimauchi R, Nishibori N, et al. Dipeptidyl peptidase-4 inhibitors-associated bullous pemphigoid: a retrospective study of 168 pemphigoid and 9,304 diabetes mellitus patients. J Diabetes Investig. 2019;10(2):392–8. https://doi.org/10.1111/jdi.12877.CrossRefPubMed

44.

Schmidt E, Zillikens D. Pemphigoid diseases. Lancet. 2013;381(9863):320–32. https://doi.org/10.1016/s0140-6736(12)61140-4.CrossRefPubMed

45.

Ujiie H, Muramatsu K, Mushiroda T, et al. HLA-DQB1*03:01 as a biomarker for genetic susceptibility to bullous pemphigoid induced by DPP-4 inhibitors. J Invest Dermatol. 2018;138(5):1201–4. https://doi.org/10.1016/j.jid.2017.11.023.CrossRefPubMed

46.

Ueki K, Sasako T, Okazaki Y, et al. Effect of an intensified multifactorial intervention on cardiovascular outcomes and mortality in type 2 diabetes (J-DOIT3): an open-label, randomised controlled trial. Lancet Diabetes Endocrinol. 2017;5(12):951–64. https://doi.org/10.1016/s2213-8587(17)30327-3.CrossRefPubMed

47.

Sone H, Tanaka S, Tanaka S, et al. Serum level of triglycerides is a potent risk factor comparable to LDL cholesterol for coronary heart disease in Japanese patients with type 2 diabetes: subanalysis of the Japan Diabetes Complications Study (JDCS). J Clin Endocrinol Metab. 2011;96(11):3448–56. https://doi.org/10.1210/jc.2011-0622.CrossRefPubMed

48.

Kasuga M, Ueki K, Tajima N, et al. Report of the JDS/JCA Joint Committee on Diabetes and Cancer. Diabetol Int. 2013;4(2):81–96. https://doi.org/10.1007/s13340-013-0121-3.CrossRef

49.

Cancer Information Service, National Cancer Center, Japan Cancer Registry and Statistics. https://ganjoho.jp/data/reg_stat/statistics/dl/cancer_incidence47pref(2014-2015).xls(in Japanese). Accessed 22 Aug 2019.

50.

Ministry of Health, Labour and Welfare (2016) Health and Nutrition Survey in Japan 2014. https://www.mhlw.go.jp/bunya/kenkou/eiyou/dl/h26-houkoku-05.pdf(in Japanese). Accessed 22 Aug 2019.

51.

Offurum A, Wagner LA, Gooden T. Adverse safety events in patients with chronic kidney disease (CKD). Expert Opin Drug Saf. 2016;15(12):1597–607. https://doi.org/10.1080/14740338.2016.1236909.CrossRefPubMed

52.

Alsahli M, Gerich JE. Hypoglycemia in patients with diabetes and renal disease. J Clin Med. 2015;4(5):948–64. https://doi.org/10.3390/jcm4050948.CrossRefPubMedPubMedCentral

53.

Gianchandani RY, Neupane S, Iyengar JJ, Heung M. Pathophysiology and management of hypoglycemia in end-stage renal disease patients: a review. Endocr Pract. 2017;23(3):353–62. https://doi.org/10.4158/ep161471.Ra.CrossRefPubMed

54.

Gupta S, Sen U. More than just an enzyme: dipeptidyl peptidase-4 (DPP-4) and its association with diabetic kidney remodelling. Pharmacol Res. 2019;147:104391. https://doi.org/10.1016/j.phrs.2019.104391.CrossRefPubMedPubMedCentral

55.

Thomas MC, Paldanius PM, Ayyagari R, Ong SH, Groop PH. Systematic literature review of DPP-4 inhibitors in patients with type 2 diabetes mellitus and renal impairment. Diabetes Ther. 2016;7(3):439–54. https://doi.org/10.1007/s13300-016-0189-4.CrossRefPubMedPubMedCentral

56.

Otsuki H, Kosaka T, Nakamura K, Shimomura F, Kuwahara Y, Tsukamoto T. Safety and efficacy of teneligliptin: a novel DPP-4 inhibitor for hemodialysis patients with type 2 diabetes. Int Urol Nephrol. 2014;46(2):427–32. https://doi.org/10.1007/s11255-013-0552-6.CrossRefPubMed

57.

Wada N, Mori K, Nakagawa C, et al. Improved glycemic control with teneligliptin in patients with type 2 diabetes mellitus on hemodialysis: evaluation by continuous glucose monitoring. J Diabetes Complications. 2015;29(8):1310–3. https://doi.org/10.1016/j.jdiacomp.2015.07.002.CrossRefPubMed

58.

Kadowaki T, Sasaki K, Ishii M, Matsukawa M, Ushirogawa Y. Efficacy and safety of teneligliptin 40 mg in type 2 diabetes: a pooled analysis of two phase III clinical studies. Diabetes Ther. 2018;9(2):623–36. https://doi.org/10.1007/s13300-018-0372-x.CrossRefPubMedPubMedCentral

Title: Long-Term, Real-World Safety and Efficacy of Teneligliptin: A Post-Marketing Surveillance of More Than 10,000 Patients with Type 2 Diabetes in Japan
Authors: Takashi Kadowaki
Masakazu Haneda
Hiroshi Ito
Kazuyo Sasaki
Miyuki Matsukawa
Yuka Yamada
Publication date: 01-03-2020
Publisher: Springer Healthcare
Keywords: Diabetes
Type 2 Diabetes
Published in: Advances in Therapy / Issue 3/2020
Print ISSN: 0741-238X
Electronic ISSN: 1865-8652
DOI: https://doi.org/10.1007/s12325-019-01189-w

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

Illustration of figure on mountain summit/© Orapun / Stock.adobe.com, STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Introduction

Methods

Results

Conclusion

Trial registration

Plain Language Summary

Please log in to get access to this content

Other articles of this Issue 3/2020

Efficacy and Safety of Intravitreal Aflibercept Treat-and-Extend Regimens in Exudative Age-Related Macular Degeneration: 52- and 96-Week Findings from ALTAIR

Revisiting Existing Evidence of Corneal Endothelial Progenitors and Their Potential Therapeutic Applications in Corneal Endothelial Dysfunction

A Real-World Analysis of Patient Characteristics and Predictors of Hospitalization Among US Medicare Beneficiaries with Respiratory Syncytial Virus Infection

SABINA: An Overview of Short-Acting β2-Agonist Use in Asthma in European Countries

Real-World Data and Randomised Controlled Trials: The Salford Lung Study

A Relative Cost of Control Analysis of Once-Weekly Semaglutide Versus Exenatide Extended-Release, Dulaglutide and Liraglutide in the UK

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage